EUVIMEDOpdag EUVIMED
Kohortenstudie

Persistence, effectiveness, and safety of CGRP ‐targeted therapies across therapeutic lines in resistant migraine: A real‐world cohort study

Eduardo Pons-Fuster iD, Iris Muñoz-García, Almudena Mancebo-González, Alberto Espuny-Miró, Celia María González-Ponce

Headache: The Journal of Head and Face Pain · 2026-11-16

DOI: 10.1111/head.70276 ↗

At a glance

Kohortenstudie in Headache: The Journal of Head and Face Pain, published online on 2026-11-16. Written by Eduardo Pons-Fuster and 4 co-authors. Institution: Clinical Pharmacy and Therapeutics Research Group, Virgen de la Arrixaca University Clinical Hospital and Biomedical Research Institute of Murcia Pas…. 28 references.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Objectives/Background Our objectives were to evaluate treatment persistence, effectiveness, safety, treatment sequencing patterns, and factors associated with treatment response in a real‐world cohort of patients with resistant migraine receiving calcitonin gene‐related peptide (CGRP)‐targeted therapies. Real‐world evidence on CGRP‐targeted therapies has primarily focused on anti‐CGRP monoclonal antibodies, whereas data regarding gepants, treatment sequencing, and determinants of treatment success remain limited. Understanding outcomes across therapeutic lines is increasingly relevant as switching between CGRP‐targeted therapies becomes common in clinical practice.

Methods

We conducted a single‐center retrospective cohort study in a tertiary hospital between June 2020 and June 2026, including adults with resistant migraine treated with anti‐CGRP monoclonal antibodies (erenumab, fremanezumab, or galcanezumab) or gepants (atogepant or rimegepant). The primary end point was treatment persistence. Secondary end points included effectiveness, safety, treatment sequencing patterns, and factors associated with treatment response. Effectiveness was defined as achievement of a ≥50% reduction in monthly migraine days (≥50% responders) at 6 and 12 months. Safety was assessed through adverse events reported during treatment.

Results

A total of 254 patients contributed 312 treatment episodes, including 254 first‐line and 58 greater than or equal to second‐line CGRP‐targeted treatment episodes. Treatment persistence was significantly higher among first‐line than greater than or equal to second‐line treatment episodes, with 12‐month persistence rates of 78.4% (95% confidence interval [CI] = 73.4–83.7) and 44.4% (95% CI = 32.1–61.2), respectively. In multivariable analyses, greater than or equal to second‐line treatment was independently associated with a higher hazard of treatment discontinuation (adjusted hazard ratio = 2.84, 95% CI = 1.73–4.66; p < 0.001). At 6 months, ≥50% responder rates were significantly higher in first‐line treatment episodes than greater than or equal to second‐line treatment episodes (133/220 [60.5%] vs. 10/34 [29.4%]; p < 0.001). No significant differences in persistence or effectiveness were observed between therapeutic classes or individual CGRP‐targeted therapies. High‐frequency episodic migraine was independently associated with higher odds of treatment response (adjusted odds ratio = 2.53, 95% CI = 1.12–5.70; p = 0.026), whereas treatment with gepants, higher baseline Migraine Disability Assessment scores, two or more migraine‐related comorbidities, concomitant onabotulinumtoxinA use, and concomitant use of other oral preventive treatments were associated with lower odds of response. Adverse events occurred in 33.2% of treatment episodes and were predominantly mild; only two grade≥3 adverse events were reported. Treatment discontinuation due to adverse events occurred in 12.5% of treatment episodes.

Conclusion

CGRP‐targeted therapies demonstrated favorable persistence, effectiveness, and tolerability in resistant migraine. Treatment line emerged as a major determinant of outcomes, with superior persistence and effectiveness observed in first‐line therapies. Nevertheless, clinically meaningful benefit was still observed in a substantial proportion of later‐line treatment episodes, suggesting that some patients may derive benefit from switching between CGRP‐targeted therapies in contemporary migraine practice.

Subjects

Author keywords

calcitonin gene‐related peptidegepantsmonoclonal antibodiesresistant migrainetreatment persistencetreatment sequencing

Authors and institutions

  • Clinical Pharmacy and Therapeutics Research Group, Virgen de la Arrixaca University Clinical Hospital and Biomedical Research Institute of Murcia Pascual Parrilla (IMIB), Murcia, Spain.

ORCID profiles: Eduardo Pons-Fuster

Cite

APA

Pons-Fuster, E., Muñoz-García, I., Mancebo-González, A., Espuny-Miró, A., & González-Ponce, C. M. (2026). Persistence, effectiveness, and safety of CGRP ‐targeted therapies across therapeutic lines in resistant migraine: A real‐world cohort study. Headache: The Journal of Head and Face Pain. https://doi.org/10.1111/head.70276

Vancouver

Pons-Fuster E, Muñoz-García I, Mancebo-González A, Espuny-Miró A, González-Ponce CM. Persistence, effectiveness, and safety of CGRP ‐targeted therapies across therapeutic lines in resistant migraine: A real‐world cohort study. Headache: The Journal of Head and Face Pain. 2026. doi:10.1111/head.70276

BibTeX
@article{PonsFuster2026,
  author = {Pons-Fuster, Eduardo and Muñoz-García, Iris and Mancebo-González, Almudena and Espuny-Miró, Alberto and González-Ponce, Celia María},
  title = {Persistence, effectiveness, and safety of CGRP ‐targeted therapies across therapeutic lines in resistant migraine: A real‐world cohort study},
  journal = {Headache: The Journal of Head and Face Pain},
  year = {2026},
  doi = {10.1111/head.70276}
}
Start for free →